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Abstract. The purpose of the research was to propound an insulin activity model in a human body after a subcutaneous injection. 
A deterministic model in the form of a mathematical function was formulated. The research was based on pharmaceutic publicly available drug 
information published by the manufactures. The paper presents in detail the model. The obtained results can be used in computer simulations of 
diabetes mellitus therapy. They suggest that activity models may be assigned to types of insulin instead of separate products. 
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Uzyskanie modelu aktywności insuliny na podstawie profili insulinowych 
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Streszczenie. Celem badań było opracowanie modelu aktywności insuliny w organizmie człowieka po wstrzyknięciu podskórnym. 
Sformułowano model deterministyczny w postaci funkcji matematycznej. Badanie oparto na publicznie dostępnych informacjach 
farmaceutycznych opublikowanych przez producentów. Artykuł szczegółowo przedstawia model. Uzyskane wyniki mogą być wykorzystane 
w komputerowych symulacjach terapii cukrzycy. Sugerują one również, że modele aktywności mogą dotyczyć grup insulin zamiast 
konkretnych preparatów. 
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1. Introduction 
The insulin activity model presented in this paper is 
intended to assist development of computer systems 
supporting type 1 diabetes therapy. The type 1 diabetes is 
an incurable (nowadays) autoimmune disease with global 
occurrence. The consequence of getting this type is the 
patient’s body inability to produce the insulin hormone. In this 
sense, a person with type 1 diabetes is a disabled person. 
Insulin is a crucial hormone for a metabolism, so it must be 
supplied from the outside a lifetime because the lack of it leads 
in short time to a coma and subsequently to death. The therapy 
with insulin is difficult and awkward. Proper doses of 
an insulin analog (artificial insulin used as a medicine) have to 
be injected a few times a day daily. Each overdose results in 
hypoglycemia (low blood sugar), which may even lead to 
sudden death. Contrarily, each under-dose brings 
hyperglycemia (high blood sugar), which in a longer time 
brings destruction of blood vessels, nerve tissues and kidneys. 
On the other hand a proper therapy means that the disability 
resulting from type 1 diabetes is almost imperceptible by the 
patient and his/her environment. Such a person is able to live 
a successful life including the professional and family sphere. 
Therefore, carrying out research on insulin dosing algorithms 
is reasoned. 
Today there are many insulin analogs in use. 
Administering such insulin to a patient is realized by 
subcutaneous injections. After an injection the whole dose of 
the insulin does not become immediately available to a human 
body, but is released into the blood system gradually. The 
process takes place in time and can be described with a insulin 
profile (Fig. from 2 to 7). The profile (sometimes called an 
insulin curve) is a characteristic of an insulin analog and tells 
how blood insulin concentration changes over time after the 
injection of a certain dose. Although the profile depends on 
many different factors, it is necessary to assume one when 
predicting an insulin action in a body. 
 
Fig. 1. Simplified insulin activity function applied in OpenAPS [1] 
The insulin profiles themselves may be used in computer 
simulations but it would not be convenient because they refer 
to blood concentration. It is more usefully to know what 
fraction of the whole insulin dose will be released in 
subsequent minutes. Such a function is called the insulin 
activity function and because building one always needs 
making assumptions it is also named the insulin activity 
model. 
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Regrettably - from digital biohackers’ point of view - 
pharmaceutical companies do not publish mathematical 
formulas for their insulin analogs. Therefore, software 
developers adopt simplified insulin activity functions. 
An example of such a function can be found in OpenAPS [1], 
which is a successful open-source  artificial pancreas system 
that got ahead commercial equivalents a few years ago. The 
system has been created by volunteers and is publicly 
available under the MIT license. The system applies the 
simplest approximation that assumes linear increase and linear 
decrease in bioavailability of an insulin dose (Fig.1). The 
creators themselves agree that the model should be replaced 
with more precise one. 
2. Analysis of insulin profiles 
2.1. Common insulin analogs 
Today the world demand for insulin is supplied by 6 
private companies [2] (Table 1). From commercial medicine 
point of view it may be said that participation in the market of 
other suppliers is marginal. For this reason, this research has 
been limited to the products of the leading manufacturers. 
Tables form 2 to 7 enumerate insulin analogs offered by the 
group of interest excluding insulin mixes. In the tables next to 
the name of an insulin analog there is given its type and the 
information about its profile availability. Generally there are 4 
types of insulin analogs defined by their time activity in 
a human body. The first group called „rapid acting” remains 
active up to 6 hours, the second one denoted „short acting” up 
to 9 hours, the next „intermediate acting” means about 12 
hours of activity and the last group „long acting” stands over 
20 hours. Having said that it must be noted that the given 
definition is rough. 
Table 1.  Major players in the world insulin market 
Company Origin Web page 
Novo Nordisk Denmark www.novonordisk.com 
Sanofi France www.sanofi.com 
Eli Lilly USA www.lilly.com 
Biocon India www.biocon.com 
Julphar UAE www.julphar.net 
Table 2.  Novo Nordisk essential insulin analogs offer 
Name Type Profile published 
Fiasp® 
Rapid 
Yes NovoRapid® 
Actrapid® Short 
Insulatard® Intermediate 
No 
Tresiba® 
Long Xultophy® 
Levemir® 
Table 3.  Sanofi essential insulin analogs offer 
Name Type Profile published 
Apidra® 
Rapid 
Yes Insuman Implantable® 
Insulin Lispro Sanofi® 
No 
Insuman R® 
Short Insuman N® 
Lantus® 
Long Toujeo® 
Table 4.  Eli Lilly essential insulin analogs offer 
Name Type Profile published 
Humalog® Rapid 
Yes 
Humulin R Short-acting® 
Short Liprolog® 
No Humulin N® Intermediate 
Abasaglar® Long 
Table 5.  Biocon essential insulin analogs offer 
Name Type Profile published 
Insugen® Short No 
Table 6.  Julphar essential insulin analogs offer 
Name Type Profile published 
Jusline N® 
Intermediate No Jusline R® 
2.2. Recognition of insulin profiles 
At the time of the research only for 7 insulin analogs there 
were insulin profiles included into the official information 
about the medical products [3-8]. The source graphs have 
been  presented in the figures from 2 to 8. 
 
Fig. 2. Insulin profile for Fiasp including points (in red) used in 
polynomial fitting [3] 
All the source graphs have been supplemented with points 
used in the calculations. The values have been obtain using the 
open-source graphical program LibreCad (www.librecad.org).  
According to the manufacturers the data came from clinical 
trials and was averaged before published. All the diagrams 
show how serum insulin concentration varies over time after 
a subcutaneous injection of a certain insulin dose. The 
diagrams are not standardized. The time is given in minutes or 
hours. The observation time ranges from 240 to 720 minutes. 
The first measurement is made at the time of the injection or 
before it. The insulin concentration is given in different units 
with or without baseline adjustment. Therefore there is a need 
to normalize the curves in order to use in any computer 
calculations. 
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Fig. 3. Insulin profile for NovoRapid including points (in red) used in 
polynomial fitting. The left column gives data read from the graph, the right 
after baseline adjustment and time converted to minutes [4] 
 
Fig. 4. Insulin profile for Actrapid including points (in red) used in 
polynomial fitting. Values given after baseline adjustment [5] 
 
Fig. 5. Insulin profile for Apidra including points (in blue) used in 
polynomial fitting where hours has been converted to minutes [6] 
 
Fig. 6. Insulin profile for  Insuman Implantable including points (in red) 
used in polynomial fitting- hours converted into minutes, concentration 
values given over the base level of 25 [7] 
 
Fig. 7. Insulin profile for Humalog including points (in blue) used in 
polynomial fitting where serum insulin concentration is given over the base 
level of 0.5 [8] 
 
Fig. 8. Insulin profile for Humulin R Short-acting including points 
(in blue) used in polynomial fitting where serum insulin concentration is 
given over the base level of 0.5 [8] 
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It was assumed that the insulin curves can be approximated  
with polynomials. After preliminary tests (results unpublished) 
it was stated that the minimal degree of such a polynomial is 
6: 

C (T )=A
6
⋅T6 +A
5
⋅T 5 +A
4
⋅T 4
+A
3
⋅T 3 +A
2
⋅T 2+A
1
⋅T+A
0  
where: C is serum insulin concentration, T - time, Ai -
 individual coefficients for each insulin analog (i=0,1,..,6). The 
polynomial is valid for the range of insulin action starting with 
the time of application (injection) TAPP until it fades away at 
time point marked  TFED. The range of insulin action is denoted 
by TSPAN = TFED – TAPP. Within the considered range there is so 
called peak insulin activity. It is just maximum of the 
polynomial function and the time point for it is denoted by 
TPEAK (TAPP < TPEAK < TFED). To simplify calculations, it was 
assumed that TAPP = 0. 
Before fitting the polynomial (1) to the points from the 
diagrams (Fig. from 2 to 8) following restrictions had been 
imposed: 
 C (T APP ) = C (T FED) = 0  
 C (T APP <T<TFED) > 0  
 C' (T PEAK) = 0  
 C' (T APP<T<T PEAK ) > 0  
 C' (T APP<T<T PEAK ) > 0  
 C' (T FED) = 0  
The condition (2) along with (3) says that the increase in 
serum insulin concentration takes place from TAPP to TFED and 
the injection itself cannot cause any decrease of the 
concentration. Satisfying the conditions (4), (5) and (6) 
together guarantees existence of one maximum within the 
range of insulin action i.e. existence of the insulin peak. 
Finally the condition (7) forces gradual asymptotic fading of 
the concentration, which can be noticed for all presented 
insulin analogs. Minutes were used as time unit and the point 
of the peak was searched for with 5 minutes resolution. This 
approach let keep the results practical with the therapeutic 
point of view. Moreover any greater accuracy would not have  
correspond with the source data, which had been after all 
averaged. 
All the symbolic and numerical calculations were 
preformed using the open-source mathematics software 
SageMath (www.sagemath.org). The quality of fitting the 
polynomials to the points has been shown in figures from 9 to 
15. The calculations resulted in finding the values of the Ai 
coefficients for all the insulins under study. Here the time T is 
given in minutes but the values of the polynomials correspond 
to the source units (see Fig.  from 2 to 8). The symbol P in the 
descriptions  under the figures stands for the area under the 
curve given in current units. These values were used in 
a normalization process. 
 
Fig. 9. Polynomial fitting for Fiasp: TPEAK= 55, C(T) = −4.408×10−12 T6 +6.756×10−9 T5 −4.073×10−6 T4 +1.218×10−3 T3 −0.1840 T2 +11.60 T, 
P=36452.5 
3. The model of insulin activity 
After the fitting calculations all the polynomials had been 
normalized. The normalization process consisted in 
transforming the polynomials to the range of [0,1] and 
reducing the area under the curve to 1. If the normalized form 
of (1) is described with (note small letters): 

c (t )=a
6
⋅t6 +a
5
⋅t5 +a
4
⋅t4
+a
3
⋅t3 +a
2
⋅t2+a
1
⋅t+a
0  
where: c is unitless serum insulin concentration, t -unitless 
time in the range of [0,1], then the individual coefficients ai  
for each insulin analog can be calculated using the formula: 

a
i
=
A
i
⋅T
SPAN
i+1
P  
Having the normalized insulin curves (Table 7) it is 
possible to determine insulin activity functions: 

D (T )=DOSE
T
SPAN
⋅c( TT
SPAN
)  
where: DOSE is the amout of insulin injected (in any insulin 
unit). The model of insulin activity contains the following 
assumptions: 
 Source diagrams (Fig. from 2 to 8) present the total 
consumption of the injected dose. 
 Insulin serum concentration is directly proportional to the 
active fraction of the whole dose. 
 The insulin dose size does not affect its profile. 
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Fig. 10. Polynomial fitting for NovoRapid: TPEAK= 40, 
C(T)= −1.034×10−11 T6 +1.035×10−8 T5 −4.076×10−6 T4 +8.018×10−4 T3 
−0.08134 T2 +3.576 T, P=6048.19 
 
Fig. 11. Polynomial fitting for Actrapid: TPEAK= 120, 
C(T)= −5.669×10−14 T6 +1.054×10−10 T5 −7.818×10−8 T4 +3.064×10−5 T3 
−0.006997 T2 +0.7952 T, P=9190.88 
 
Fig. 12. Polynomial fitting for Apidra: TPEAK= 65, C(T) = −3.638×10−13 T6 +7.160×10−10 T5 −5.521×10−7 T4 +2.090×10−4 T3 −0.03926 T2 +3.000 T, 
P=13354.3 
 
Fig. 13. Polynomial fitting for Insuman Implantable: TPEAK= 35, 
C(T)= −1.351×10−11 T6 +1.846×10−8 T5 −9.040×10−6 T4 +2.060×10−3 T3 
−0.2239 T2 +9.519 T, P=11320.0 
 
Fig. 14. Polynomial fitting for Humalog: TPEAK= 60, C(T)= −1.670×10−20 
T6 +9.683×10−12 T5 −1.040×10−8 T4 +4.214×10−6 T3 −0.0007752 T2 +0.05588 
T, P=192.583 
 
Fig. 15. Polynomial fitting for Humulin R Short-acting: TPEAK= 140, 
C(T)= +2.296×10−15 T6 −3.739×10−12 T5 +2.227×10−9 T4 −5.197×10−7 T3 
+4.667×10−6 T2 +0.0113 T, P=221.561 
4. Results 
The most valuable results of this work are the normalized 
insulin profiles given by polynomial coefficients ai (Table 7). 
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The profiles enable standarized comparison of insulin analogs. 
Moreover they, along with the time ranges of insulin action 
TSPAN, let formulate the insulin activity model according to 
(10). The normalized curves have been depicted in the 
following figures. The Fig.16 presents the curves for the rapid 
acting insulin analogs under study, whereas the Fig. 17 shows 
the curves for the short acting analogs. It can be noticed that 
within the the same group the normalized insulin curves are 
similar. The differences between them may not go beyond 
measurement scatter. Let’s take into consideration Fig. 2 and 
Fig. 3. They both  show insulin profiles for NovoRapid. Using 
the data from the figures two different normalized curves for 
the same analog have been draw up (see Fig. 18). The 
disagreement is similar to that one seen between different 
rapid acting analogs (Fig. 16). This observation indicates 
a possible direction in further searching for insulin activity 
models. It suggests that it may be possible to use one 
normalized insulin curve for each group instead of individual 
for each product. 
Example activity functions have been calculated according 
to (10) for DOSE = 1U (1unit) and presented at Fig. 19. The 
functions describe the action of 1U of an insulin analog 
injected at time TAPP=0. The figure shows how the analogs 
activates in a human body over time.  In this case different 
types of  insulin can be presented at the same graph, because 
here unitless time is scaled to real minutes using the given 
periods of activity TSPAN. Looking at the figure is easy to point 
out the rapid acting group and the short acting group. 
The case of Humalg needs to be commented. Looking at 
the Fig. 19 one can notice that its curve deviates from the rest 
of the rapid-acting group. The graph suggests that Humalog is 
the fastest insulin. The effect is not present in the Fig. 16 
because it is the activity time range TSPAN that has decided on 
the look of the activity function. The range for Humalog (see 
Table 7) is shorter then ranges of other rapid-acting analogs. 
The range was read form Fig. 6. The author of this paper 
recommends caution in this case. 
 
Fig. 16. Normalized insulin curves for rapid acting analogs under study 
Table 7.  Unitless coefficients ai (i=1, 2, ..,6, a0=0 for each case) of 
normalized insulin curves and time ranges of insulin action in minutes 
Insulin a6  a5 a4 a3 a2 a1 TSPAN 
Fiasp 
−9
4
.7
6
 
+
4
0
3
.4
 
−6
7
5
.6
 
+
5
6
1
.2
 
−2
35.
5 
+
4
1
.2
5
 
360 
NovoRapid 
−7
8
.4
4
 
+
3
2
7
.1
 
−5
3
6
.6
 
+
4
3
9
.8
 
−1
8
5
.9
 
+
3
4
.0
5
 
360 
Actrapid 
−5
5
.3
5
 
+
2
0
1
.8
 
−2
9
3
.5
 
+
2
2
5
.5
 
−1
0
1
.0
 
+
2
2
.5
0
 
510 
Apidra 
−1
5
9
.9
 
+
6
5
5
.7
 
−1
0
5
3
 
+
8
3
1
.0
 
−3
2
5
.2
 
+
5
1
.7
5
 
480 
Insuman 
Implantable −5
4
.7
2
 
+
3
1
1
.7
 
−6
3
5
.9
 
+
6
0
3
.9
 
−2
7
3
.5
 
+
4
8
.4
3
 
240 
Humalog 
+
0
.0
0
0
 
+
6
4
.9
3
 
−2
1
1
.3
 
+
2
5
9
.5
 
−1
4
4
.7
 
+
3
1
.6
0
 
330 
Humulin R 
+
6
0
.8
4
 
−2
0
6
.4
 
+
2
5
6
.1
 
−1
2
4
.5
 
+
2
.3
2
9
 
+
1
1
.7
0
 
48 
 
Fig. 17. Normalized insulin curves for short acting analogs under study 
 
Fig. 18. Insulin profile for NovoRapid acc.to different data sources 
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Fig. 19. Insulin activity functions acc.to (10) for the analogs under study 
after injection of 1U (unit) of insulin analog 
5. Conclusion 
In this paper 7 normalized insulin profiles have been 
evaluated based on the product information published by the 
manufactures. Followingly, the insulin activity model has been 
propounded. The model consists of a function formula which 
enables to predict insulin activity in a human body after an 
injection. The activity model may be used with limited trust (!) 
in computer aided therapy of type 1 diabetes. Moreover the 
results have opened a new direction for future research in the 
field of insulin activity models.  
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